Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 1, 2013, Pages

  Hazlewood, Glen S ^a   Barnabe, Cheryl ^b   Tomlinson, George ^c   Marshall, Deborah ^d   Bombardier, Claire ^e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e INSTITUTE FOR WORK AND HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CHLOROQUINE; CYCLOSPORINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB;

ADVERSE EVENT; ARTICLE; BLOOD TOXICITY; CLINICAL OUTCOME; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG RESPONSE; DRUG TOXICITY; DRUG WITHDRAWAL; FATIGUE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; META ANALYSIS; MONOTHERAPY; NETWORK META-ANALYSIS; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TOXIC HEPATITIS;

EID: 84964669061     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010227     Document Type: Article

References (42)

1. Ades AE, Sculpher M, Sutton A, Abrams K, Cooper N, Welton N, et al.Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006;24:1-19.
2. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al.2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases 2010;69:1580-8.
3. Anzures-Cabrera J, Sarpatwari A, Higgins JP. Expressing findings from meta-analyses of continuous outcomes in terms of risks. Statistics in Medicine 2011;30:2967-85.
4. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al.The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis & Rheumatism 1988;31:315-24.
5. Bingham S, Emery P. Combination therapy in rheumatoid arthritis. Springer Seminars in Immunopathology 2001;23:165-83.
6. Braun J, Rau R. An update on methotrexate. Current Opinion in Rheumatology 2009;21:216-23.
7. Brooks S, Gelman A. General methods for monitoring convergence of iterative simulations. Journal of Computational and Graphical Statistics 1998;7:434-55.
8. Bykerk VP, Akhavan P, Hazlewood GS, Schieir O, Dooley A, Haraoui B, et al.Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. The Journal of Rheumatology 2012;39:1559-82.
9. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Statistics in Medicine 2010;29:932-44.
10. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al.American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis & Rheumatism 1995;38:727-35.
11. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
12. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. The Journal of Rheumatology 1982;9:789-93.
13. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, et al.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Annals of the Rheumatic Diseases. 2012;71 Suppl 2:i2-45.
14. Gossec L, Dougados M, Rincheval N, Balanescu A, Boumpas DT, Canadelo S, et al.Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Annals of the Rheumatic Diseases. 2009;68:1680-5.
15. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
16. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
17. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, et al.Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value in Health 2011;14:429-37.
18. Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. The Journal of Rheumatology 2004;31:645-8.
19. Jansen JP, Crawford B, Bergman G, Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value in Health 2008;11:956-64.
20. Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, et al.Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value in Health 2011;14:417-28.
21. Katchamart W, Trudeau J, Phumethum V, Bombardier C. Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI: 10.1002/14651858.CD008495]
22. Klareskog L, Padyukov L, Rönnelid J, Alfredsson L. Genes, environment and immunity in the development of rheumatoid arthritis. Current Opinion in Immunology 2006;18:650-5.
23. Knevel R, Schoels M, Huizinga TW, Aletaha D, Burmester GR, Combe B, et al.Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases 2010;69:987-94.
24. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004;22:1-12.
25. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiologica: Diagnosis (Stockh) 1977;18:481-91.
26. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, et al.A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The treatment of early aggressive rheumatoid arthritis trial. Arthritis & Rheumatism 2012;64:2824-35.
27. Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, et al.Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Annals of the Rheumatic Diseases 2010;69:976-86.
28. National Institute for Clinical Excellence (NICE). Rheumatoid Arthritis: The management of rheumatoid arthritis in adults: NICE clinical guidance 79. February 2009. Available from www.nice.org.uk.
29. Platt RW, Leroux BG, Breslow N. Generalized linear mixed models for meta-analysis. Statistics in Medicine 1999;18:643-54.
30. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis and Rheumatism 1995;38:44-8.
31. The R Foundation for Statistical Computing. R. 2.14.0. The R Foundation for Statistical Computing, 2011.
32. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al.American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Care & Research 2008;59:762-84.
33. Sanderson T, Morris M, Calnan M, Richards P, Hewlett S. Patient perspective of measuring treatment efficacy: the rheumatoid arthritis patient priorities for pharmacologic interventions outcomes. Arthritis Care & Research (Hoboken) 2010;62:647-56.
34. Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis and Rheumatism 1971;14:706-20.
35. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al.Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI: 10.1002/14651858.CD007848.pub2]
36. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases 2010;69:964-75.
37. Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bulletin of the NYU Hospital for Joint Diseases 2007;65:168-73.
38. van der Heijde DM, van't Hof MA, van Riel PL, van Leeuwen MA, van Rijswijk MH, van de Putte LB. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Annals of the Rheumatic Diseases 1992;51:177-81.
39. van der Heijde DM. How to read radiographs according to the Sharp/van der Heijde method. The Journal of Rheumatology 2000;27:261-3.
40. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis and Rheumatism 1996;39:34-40.
41. van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Cöster L, Waltbrand E, et al.Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009; Vol. 374:459-66.
42. Imperial College and Medical Research Council. WinBUGS. 1.4.3. Cambridge, UK: Imperial College and Medical Research Council, Aug 6, 2007.